As the extensive crossover of the MAPK and PI3K/AKT/mTOR signalling cascades have been described thus far, it is no wonder that targeting broad effector molecules such as AKT, mTOR, or BRAF/MEK have proven difficult as a treatment strategy in glioblastoma. The gene discussed is PIK3CD; the disease is glioblastoma.